AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Mar 2, 2021
29864_dirs_2021-03-02_382a69ee-480a-487d-94a9-28d3d1fe0bd1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-26
Reporting Person: Silva Paul M (SVP & Chief Accounting Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-26 | Common Stock | F | 2218 | $212.42 | Disposed | 12666 | Direct |
| 2021-03-01 | Common Stock | S | 1026 | $210.13 | Disposed | 11640 | Direct |
| 2021-03-01 | Common Stock | S | 610 | $211.45 | Disposed | 11030 | Direct |
| 2021-03-01 | Common Stock | S | 915 | $212.51 | Disposed | 10115 | Direct |
| 2021-03-01 | Common Stock | S | 231 | $213.12 | Disposed | 9884 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 169 | Indirect |
Footnotes
F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77).
F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95).
F5: Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85).
F6: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27).